 |
|
Systemic Lupus ErythematosusAssociation With Psoralen-Ultraviolet-A Treatment of Psoriasis
Steven Eyanson, MD;
Mary C. Greist, MD;
Kenneth D. Brandt, MD;
Boyd Skinner, MD
Arch Dermatol. 1979;115(1):54-56.
Abstract
Systemic lupus erythematosus (SLE) developed in a 23-year-old woman with psoriasis during treatment with psoralen-ultraviolet-A (PUVA). The connective tissue disease was characterized by an erythematous rash, hair loss, nephritis, splenomegaly, seizures, and coma. Serum antinuclear antibodies were present in high titer, and hypocomplementemia developed. Antibodies to native or ultraviolet-irradiated DNA were not demonstrated. While the association of psoriasis and lupus may have been fortuitous, the temporal relationships suggest that PUVA treatment in this case may have been of pathogenetic importance in the development of the connective tissue disease.
(Arch Dermatol 115:54-56, 1979)
Author Affiliations
From the Rheumatology Division (Drs Eyanson and Brandt) and the Dermatology Department (Drs Greist and Skinner), Indiana University School of Medicine, Indianapolis.
Footnotes
Accepted for publication Aug 25, 1978.
Reprint requests to the Rheumatology Division, Indiana University School of Medicine, 1100 W Michigan St, Indianapolis, IN 46202 (Dr Brandt).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Long-term Risks of Psoralen and UV-A Therapy for Psoriasis
Farber et al.
Arch Dermatol 1983;119:426-431.
ABSTRACT
Antinuclear Antibodies and PUVA Photochemotherapy
Kubba et al.
Arch Dermatol 1981;117:474-477.
ABSTRACT
Antinuclear Antibodies and Oral Methoxsalen Photochemotherapy (PUVA) for Psoriasis
Stern et al.
Arch Dermatol 1979;115:1320-1324.
ABSTRACT
|
